A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
- Conditions
- Depression, PostpartumDepression, Post-PartumPostnatal DepressionPostpartum Depression (PPD)Post-Natal DepressionPeripartum Depression
- Interventions
- Drug: LPCN 1154ADrug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06979544
- Locations
- 🇺🇸
Advance Research Center, Anahiem, California, United States
🇺🇸Alliance Research Institute, Canoga Park, California, United States
🇺🇸Excell Research, Inc., Oceanside, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04874350
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04685993
- Locations
- 🇺🇸
Sun Research Institute, San Antonio, Texas, United States
🇺🇸Sensible Healthcare, LLC, Ocoee, Florida, United States
🇺🇸Clinical Trials Research, Roseville, California, United States
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Drug: LPCN 1144 Formulation ADrug: PlaceboDrug: LPCN 1144 Formulation B
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04134091
- Locations
- 🇺🇸
R&H Clinical Research, Katy, Texas, United States
🇺🇸TriWest Research Associates, LLC, El Cajon, California, United States
🇺🇸United Medical Doctors, Murrieta, California, United States
Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT03868059
- Locations
- 🇺🇸
Neostart Corporation dba AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States
🇺🇸Aventiv Research, Inc., Columbus, Ohio, United States
Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03242408
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03242590
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
- Conditions
- Male Hypogonadism
- Interventions
- Drug: Oral testosterone undecanoate, LPCN 1021Drug: Topical testosterone gel 1.62 %
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Lipocine Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT02081300